サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427947

膵臓がん診断の世界市場レポート 2024

Pancreatic Cancer Diagnostic Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
膵臓がん診断の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

膵臓がん診断の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.0%の年間複合成長率（CAGR）で57億4,000万米ドルに成長すると予想されます。予測期間で予想される成長は、リキッドバイオプシー技術の進歩、標的療法の開発、診断における人工知能の統合、個別化医療アプローチの採用、早期検出バイオマーカーの特定など、いくつかの重要な要因によるものと考えられます。そして術前補助療法の利用。予測期間中に予想される主な動向には、免疫療法の調査、画像技術の進歩、外科技術の革新、世界の共同調査の取り組み、ビッグデータ分析の統合が含まれます。これらの動向は総合的に、予測される期間内でのこの分野の戦略とテクノロジーの予測される拡大と進化に貢献します。

膵臓がん診断市場の予想される成長は、膵臓がんの有病率の増加によって促進されると予想されます。膵臓組織における悪性細胞の発生を特徴とする膵臓がんは増加傾向にあり、その主な原因として、喫煙、糖尿病、慢性膵炎、膵臓がんの家族歴、膵臓の炎症、特定の遺伝性疾患などが挙げられます。膵臓がんの診断は、治療の決定を導き、がんの病期を決定し、特定の腫瘍の特徴を特定し、治療法を調整して転帰を高め、患者ケアを最適化するために非常に重要です。米国臨床腫瘍学会によると、2023年には米国で64,050人が膵臓がんと診断されると推定されており、女性では8番目に多く、男性では10番目に多いがんとなっています。膵臓がんの新たな症例の発生率は、男性と女性の両方で年間約1%ずつ増加しています。したがって、膵臓がんの罹患率の増加は、膵臓がん診断市場の拡大の重要な推進力となっています。

膵臓がん診断市場の成長はヘルスケア支出の増加です。ヘルスケア支出には、特定の地域、国、または組織のヘルスケア部門に割り当てられた財源の合計が含まれます。この支出は、患者の転帰と生存率の向上を目的として、早期発見、正確な病期分類、タイムリーな介入を促進するために膵臓がん診断に当てられます。 2023年3月、米国医師協会は、2021年の米国の医療支出は2.7%増加し、4兆3,000億米ドル、つまり1人当たり1万2,914米ドルに達すると報告しました。ヘルスケア支出の増加傾向は、膵臓がん診断市場の成長を促進する上で重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の膵臓がん診断市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 機器
  • 消耗品
  • サービス
  • 世界の膵臓がん診断市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 手術
  • 化学療法
  • 放射線治療
  • 標的療法
  • 世界の膵臓がん診断市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 外分泌
  • 腺がん
  • 扁平上皮がん
  • 腺扁平上皮がん
  • 膠質がん
  • 内分泌
  • 世界の膵臓がん診断市場、検査タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 画像検査
  • 生検
  • 血液検査
  • ゲノム検査
  • その他のテストタイプ
  • 世界の膵臓がん診断市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 診断センター
  • がん研究センター
  • 学術機関
  • 外来手術センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の膵臓がん診断市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の膵臓がん診断市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 膵臓がん診断市場の競合情勢
  • 膵臓がん診断市場の企業プロファイル
    • Pfizer Inc.
    • Hitachi Medical Corporation
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Bristol-Myers Squibb Company

第31章 その他の大手および革新的な企業

  • Thermo Fisher Scientific Inc.
  • AstraZeneca plc
  • Abbott Laboratories Inc.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • FUJIFILM Corporation
  • Becton Dickinson and Company
  • Koninklijke Philips NV
  • GE Healthcare Bio Sciences AB
  • Laboratory Corporation of America Holdings
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Qiagen Inc.
  • Myriad Genetics Inc.
  • Canon Medical Systems Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13791

Pancreatic cancer diagnostics involve the procedures and techniques employed to identify, classify, and stage pancreatic cancer, aiming to ascertain the condition's nature, assess disease severity, and guide treatment decisions. This diagnostic approach is commonly applied to address different types of pancreatic cancer, including adenocarcinoma, squamous cell carcinoma, and insulinoma.

The primary categories of pancreatic cancer diagnostic products comprise instruments, consumables, and services. Instruments refer to tools or devices utilized to perform specific tasks or achieve desired outcomes during diagnostic procedures, often involving the manipulation or examination of biological tissue. Various treatment modalities, such as surgery, chemotherapy, radiation therapy, and targeted therapy, are employed to address different types of pancreatic cancer, including exocrine, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, colloid carcinoma, and endocrine. Diagnostic tests encompass a range of methods, including imaging tests, biopsies, blood tests, genomic tests, among others. These tests are utilized by diverse end-users, including hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and other healthcare facilities.

The pancreatic cancer diagnostic market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer diagnostic market statistics, including pancreatic cancer diagnostic industry global market size, regional shares, competitors with a pancreatic cancer diagnostic market share, detailed pancreatic cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer diagnostic industry. This pancreatic cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer diagnostic market size has grown strongly in recent years. It will grow from $3.92 billion in 2023 to $4.21 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed during the historic period can be credited to several factors, including the expansion of genomic and molecular profiling, advancements in chemotherapy, refinements in radiation therapy, ongoing research on pancreatic cancer genetics, and concerted efforts through awareness campaigns and early detection initiatives. These elements collectively contributed to the progress and improvement in addressing pancreatic cancer during the specified historical timeframe.

The pancreatic cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period can be ascribed to several key factors, including advancements in liquid biopsy techniques, the development of targeted therapies, the integration of artificial intelligence in diagnostics, the adoption of personalized medicine approaches, the identification of early detection biomarkers, and the utilization of neoadjuvant therapies. Major trends expected in the forecast period encompass research in immunotherapy, progress in imaging technologies, innovations in surgical techniques, global collaborative research initiatives, and the integration of big data analytics. These trends collectively contribute to the projected expansion and evolution of strategies and technologies in the field during the forecasted timeframe.

The anticipated growth in the pancreatic cancer diagnostic market is expected to be propelled by the increasing prevalence of pancreatic cancer. Pancreatic cancer, characterized by the development of malignant cells in the pancreas tissues, is on the rise, primarily attributed to factors such as smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, inflammation of the pancreas, and certain genetic disorders. Diagnosing pancreatic cancer is crucial for guiding treatment decisions, determining the cancer stage, identifying specific tumor characteristics, and tailoring treatment approaches to enhance outcomes and optimize patient care. According to the American Society of Clinical Oncology in 2023, it is estimated that 64,050 individuals in the United States will be diagnosed with pancreatic cancer, making it the eighth most common cancer in women and the tenth most common in men. The incidence of new cases of pancreatic cancer has been increasing by about 1% per year in both men and women. Consequently, the growing prevalence of pancreatic cancer is a significant driver behind the expansion of the pancreatic cancer diagnostic market.

The growth of the pancreatic cancer diagnostic market is the increase in healthcare spending. Healthcare spending encompasses the total financial resources allocated to the healthcare sector in a specific region, country, or organization. This spending is directed towards pancreatic cancer diagnostics to facilitate early detection, accurate staging, and timely interventions, with the goal of improving patient outcomes and survival rates. In March 2023, the American Medical Association reported a 2.7% increase in health spending in the United States in 2021, reaching $4.3 trillion, or $12,914 per capita. The upward trend in healthcare spending is playing a significant role in driving the growth of the pancreatic cancer diagnostic market.

Product innovations stand out as a prominent trend gaining traction in the pancreatic cancer diagnostic market, with companies actively adopting innovative solutions to maintain their competitive positions. One noteworthy example is the introduction of Prestige Biopharma Limited's first-in-class PAUF-detecting diagnostic kit in March 2023. This diagnostic tool is designed for the early detection of pancreatic cancer, leveraging the identification of PAUF (Pancreatic Adenocarcinoma Upregulated Factor), a unique tumor-specific biomarker associated with early metastasis and prevalent in approximately 80% of pancreatic cancer cases. The innovative diagnostic technique exhibits high sensitivity and specificity in identifying PAUF, with preliminary studies indicating nearly a 1.9 times higher expression level of PAUF in the blood plasma of pancreatic cancer patients compared to healthy individuals, as reported by Prestige Biopharma's Innovative Discovery Center.

A focus on developing screening tests for pancreatic cancer is another notable strategy among major companies in the pancreatic cancer diagnostic market. Screening tests are designed to detect the presence of pancreatic cancer at an early, asymptomatic stage, enabling timely intervention and improving treatment outcomes. An example is the N-NOSE plus Pancreas test launched by Hirotsu Bio Science in December 2022. This test, marketed directly to consumers in Japan, utilizes the olfactory senses of nematodes, tiny worms, for pancreatic cancer detection.

In August 2021, Illumina Inc., a US-based healthcare company, made a significant move by acquiring GRAIL for $7.1 billion. This acquisition aims to accelerate the adoption of next-generation sequencing (NGS)-based early multi-cancer detection tests, particularly the Galleri test for pancreatic cancer. Illumina's strategic move enhances its position in clinical genomics, aiming to make the Galleri test more widely accessible in doctors' offices, as GRAIL is a US-based healthcare company specializing in early-detection blood tests for various cancers, including pancreatic cancer.

Major companies operating in the pancreatic cancer diagnostic market report are Pfizer Inc., Hitachi Medical Corporation, F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Biological Dynamics Inc., Berg LLC, Abcodia Ltd., Acobiom, Amplified Sciences LLC, Avant Diagnostics Inc., Axim Biotechnologies Inc., Alaunus Biosciences Inc., Advanced Marker Discovery SL, Anixa Diagnostics Corporation

North America was the largest region in the pancreatic cancer diagnostic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pancreatic cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic cancer diagnostic market includes revenues earned by entities through computerized tomography (CT) scans, Magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The pancreatic cancer diagnostic market consists of sales of tumor markers and drugs such as Abraxane, Afinitor, and Capecitabine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Diagnostic Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic cancer diagnostic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic cancer diagnostic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Instruments; Consumables; Services
  • 2) By Treatment: Surgery; Chemotherapy; Radiation Therapy; Targeted Therapy
  • 3) By Cancer Type: Exocrine; Adenocarcinoma; Squamous Cell Carcinoma; Adenosquamous Carcinoma; Colloid Carcinoma; Endocrine
  • 4) By Test Type: Imaging Test; Biopsy; Blood Test; Genomic Test; Other Test Types
  • 5) By End-User: Hospitals; Diagnostic Centers; Cancer Research Centers; Academic Institutes; Ambulatory Surgical Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Hitachi Medical Corporation; F. Hoffmann-La Roche AG; Novartis AG; Bristol-Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Diagnostic Market Characteristics

3. Pancreatic Cancer Diagnostic Market Trends And Strategies

4. Pancreatic Cancer Diagnostic Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pancreatic Cancer Diagnostic Market Size and Growth

  • 5.1. Global Pancreatic Cancer Diagnostic Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pancreatic Cancer Diagnostic Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pancreatic Cancer Diagnostic Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pancreatic Cancer Diagnostic Market Segmentation

  • 6.1. Global Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Instruments
  • Consumables
  • Services
  • 6.2. Global Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • 6.3. Global Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Exocrine
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Adenosquamous Carcinoma
  • Colloid Carcinoma
  • Endocrine
  • 6.4. Global Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Imaging Test
  • Biopsy
  • Blood Test
  • Genomic Test
  • Other Test Types
  • 6.5. Global Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Diagnostic Centers
  • Cancer Research Centers
  • Academic Institutes
  • Ambulatory Surgical Centers
  • Other End-Users

7. Pancreatic Cancer Diagnostic Market Regional And Country Analysis

  • 7.1. Global Pancreatic Cancer Diagnostic Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pancreatic Cancer Diagnostic Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pancreatic Cancer Diagnostic Market

  • 8.1. Asia-Pacific Pancreatic Cancer Diagnostic Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pancreatic Cancer Diagnostic Market

  • 9.1. China Pancreatic Cancer Diagnostic Market Overview
  • 9.2. China Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pancreatic Cancer Diagnostic Market

  • 10.1. India Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pancreatic Cancer Diagnostic Market

  • 11.1. Japan Pancreatic Cancer Diagnostic Market Overview
  • 11.2. Japan Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pancreatic Cancer Diagnostic Market

  • 12.1. Australia Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pancreatic Cancer Diagnostic Market

  • 13.1. Indonesia Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pancreatic Cancer Diagnostic Market

  • 14.1. South Korea Pancreatic Cancer Diagnostic Market Overview
  • 14.2. South Korea Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pancreatic Cancer Diagnostic Market

  • 15.1. Western Europe Pancreatic Cancer Diagnostic Market Overview
  • 15.2. Western Europe Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pancreatic Cancer Diagnostic Market

  • 16.1. UK Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pancreatic Cancer Diagnostic Market

  • 17.1. Germany Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pancreatic Cancer Diagnostic Market

  • 18.1. France Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pancreatic Cancer Diagnostic Market

  • 19.1. Italy Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pancreatic Cancer Diagnostic Market

  • 20.13. Spain Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pancreatic Cancer Diagnostic Market

  • 21.1. Eastern Europe Pancreatic Cancer Diagnostic Market Overview
  • 21.2. Eastern Europe Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pancreatic Cancer Diagnostic Market

  • 22.1. Russia Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pancreatic Cancer Diagnostic Market

  • 23.1. North America Pancreatic Cancer Diagnostic Market Overview
  • 23.2. North America Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pancreatic Cancer Diagnostic Market

  • 24.1. USA Pancreatic Cancer Diagnostic Market Overview
  • 24.2. USA Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pancreatic Cancer Diagnostic Market

  • 25.1. Canada Pancreatic Cancer Diagnostic Market Overview
  • 25.2. Canada Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pancreatic Cancer Diagnostic Market

  • 26.1. South America Pancreatic Cancer Diagnostic Market Overview
  • 26.2. South America Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pancreatic Cancer Diagnostic Market

  • 27.1. Brazil Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pancreatic Cancer Diagnostic Market

  • 28.1. Middle East Pancreatic Cancer Diagnostic Market Overview
  • 28.2. Middle East Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pancreatic Cancer Diagnostic Market

  • 29.1. Africa Pancreatic Cancer Diagnostic Market Overview
  • 29.2. Africa Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pancreatic Cancer Diagnostic Market Competitive Landscape And Company Profiles

  • 30.1. Pancreatic Cancer Diagnostic Market Competitive Landscape
  • 30.2. Pancreatic Cancer Diagnostic Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Hitachi Medical Corporation
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bristol-Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pancreatic Cancer Diagnostic Market Other Major And Innovative Companies

  • 31.1. Thermo Fisher Scientific Inc.
  • 31.2. AstraZeneca plc
  • 31.3. Abbott Laboratories Inc.
  • 31.4. Danaher Corporation
  • 31.5. Siemens Healthcare GmbH
  • 31.6. FUJIFILM Corporation
  • 31.7. Becton Dickinson and Company
  • 31.8. Koninklijke Philips N.V.
  • 31.9. GE Healthcare Bio Sciences AB
  • 31.10. Laboratory Corporation of America Holdings
  • 31.11. Agilent Technologies Inc.
  • 31.12. Illumina Inc.
  • 31.13. Qiagen Inc.
  • 31.14. Myriad Genetics Inc.
  • 31.15. Canon Medical Systems Corporation

32. Global Pancreatic Cancer Diagnostic Market Competitive Benchmarking

33. Global Pancreatic Cancer Diagnostic Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pancreatic Cancer Diagnostic Market

35. Pancreatic Cancer Diagnostic Market Future Outlook and Potential Analysis

  • 35.1 Pancreatic Cancer Diagnostic Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pancreatic Cancer Diagnostic Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pancreatic Cancer Diagnostic Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer